Analysis of both MYC and HSF1 copy numbers indicated that MYC had amplification in 11% (1,132/9,950) of human cancers, whereas HSF1 was amplified in 8% (840/9,950) of cancers with an overlap in a substantial number of patients (Fig. 1C). Here, MYC is linked to cancer.